SAFETY AND TOLERABILITY OF NATALIZUMAB IN SUBJECTS WITH MULTIPLE SCLEROSIS WHO H

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。Biogen Idec Inc.正在研究Natalizumab。(the本研究的申办者）与Elan Pharmaceuticals，Inc.合作，作为治疗多发性硬化症（MS）的一种可能的新方法。人们希望那他珠单抗可以防止某些类型的白色血细胞从血液中进入器官，包括大脑，这些器官被自身免疫性疾病（一种身体自身免疫系统攻击某些器官的疾病）破坏。这些白色血细胞被认为会引起炎症，从而导致大脑损伤（小面积损伤）。这些病变被认为是MS复发和残疾的原因。本研究的目的是确定那他珠单抗在复发缓解型MS患者中是否安全且耐受良好。此外，Biogen Idec还将评估人们是否会产生那他珠单抗抗体（一种蛋白质，有时当一个人暴露于体内通常不存在的蛋白质时会产生）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Natalizumab is being investigated by Biogen Idec Inc. (the sponsor of this research study), in partnership with Elan Pharmaceuticals, Inc., as a possible new treatment for multiple sclerosis (MS). It is hoped that natalizumab may prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS. The purpose of this study is to determine whether natalizumab is safe and well-tolerated in individuals with relapsing-remitting MS over an extended period of time. In addition, Biogen Idec will also evaluate whether people make antibodies (a protein that is made sometimes when a person is exposed to a protein that is not normally found in the body) to natalizumab.